Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board reduced its stake in Alnylam Pharmaceuticals by 65.2% in the first quarter, holding 60,532 shares valued at approximately $16.35 million by the end of the period.
• Alnylam Pharmaceuticals reported substantial earnings, with an EPS of $0.32 against expectations of ($0.54), and a revenue increase of 17.3% year-over-year, totaling $773.69 million.
• Research firms have shown strong optimism for Alnylam, with multiple upgrades and a majority of analysts rating the stock as a "buy", reflecting a positive outlook on its price targets.

Canada Pension Plan Investment Board cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 65.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 60,532 shares of the biopharmaceutical company's stock after selling 113,489 shares during the quarter. Canada Pension Plan Investment Board's holdings in Alnylam Pharmaceuticals were worth $16,345,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALNY. Iron Triangle Partners LP purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $17,662,000. Ieq Capital LLC boosted its stake in Alnylam Pharmaceuticals by 13.4% during the first quarter. Ieq Capital LLC now owns 44,014 shares of the biopharmaceutical company's stock worth $11,885,000 after buying an additional 5,208 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its holdings in Alnylam Pharmaceuticals by 137.2% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 23,763 shares of the biopharmaceutical company's stock valued at $6,416,000 after buying an additional 13,745 shares in the last quarter. Comerica Bank grew its holdings in Alnylam Pharmaceuticals by 23.3% in the 1st quarter. Comerica Bank now owns 17,253 shares of the biopharmaceutical company's stock valued at $4,659,000 after buying an additional 3,262 shares in the last quarter. Finally, Jump Financial LLC increased its stake in shares of Alnylam Pharmaceuticals by 3.8% in the 1st quarter. Jump Financial LLC now owns 15,717 shares of the biopharmaceutical company's stock worth $4,244,000 after acquiring an additional 572 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several recent research reports. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Piper Sandler boosted their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a report on Friday, August 1st. UBS Group increased their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Finally, Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $417.38.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the sale, the director owned 16,804 shares in the company, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock worth $25,551,456 over the last 90 days. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Down 0.3%

NASDAQ:ALNY traded down $1.54 during trading hours on Friday, reaching $452.00. 751,495 shares of the stock were exchanged, compared to its average volume of 1,057,829. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $469.81. The business has a 50-day moving average of $387.47 and a two-hundred day moving average of $310.11. The company has a market capitalization of $59.25 billion, a price-to-earnings ratio of -183.00 and a beta of 0.32. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.